APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hyperthermia Therapy for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hyperthermia Therapy for Cancer Market Outlook and Growth Opportunities 2026

8 January 2026193 pages

Choose your research edition.

Industry ResearchHyperthermia Therapy for Cancer Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Hyperthermia Therapy for Cancer Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Hyperthermia Therapy for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hyperthermia Therapy for Cancer Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hyperthermia Therapy for Cancer Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Hyperthermia Therapy for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hyperthermia Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hyperthermia Therapy for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hyperthermia Therapy for Cancer market include Pyrexar Medical, Oncotherm, Andromedic, Yamamoto Vinita, Med-Logix, Thermofield, Celsius42, Dongseo Medicare and ThermaSolutions, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hyperthermia Therapy for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hyperthermia Therapy for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hyperthermia Therapy for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hyperthermia Therapy for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Hyperthermia Therapy for Cancer Segment by Company

Pyrexar Medical

Oncotherm

Andromedic

Yamamoto Vinita

Med-Logix

Thermofield

Celsius42

Dongseo Medicare

ThermaSolutions

Verthermia

Combat Medical

Hydrosun

RanD Biotech

Shenzhen ET Medical Technology

Jiangsu Nova Medical Equipment

Hyperthermia Therapy for Cancer Segment by Type

Superficial Hyperthermia

Deep Regional Hyperthermia

Hyperthermia Therapy for Cancer Segment by Application

Breast Cancer

Cervical Cancer

Soft Tissue Sarcoma

Melanoma

Others

Hyperthermia Therapy for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hyperthermia Therapy for Cancer status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hyperthermia Therapy for Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hyperthermia Therapy for Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Hyperthermia Therapy for Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperthermia Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hyperthermia Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperthermia Therapy for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hyperthermia Therapy for Cancer market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hyperthermia Therapy for Cancer industry.

Chapter 3: Detailed analysis of Hyperthermia Therapy for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hyperthermia Therapy for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hyperthermia Therapy for Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hyperthermia Therapy for Cancer Industry Trends Table 2. Hyperthermia Therapy for Cancer Industry Drivers Table 3. Hyperthermia Therapy for Cancer Industry Opportunities and Challenges Table 4. Hyperthermia Therapy for Cancer Industry Restraints Table 5. Global Hyperthermia Therapy for Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hyperthermia Therapy for Cancer Revenue Share by Company (2021-2026) Table 7. Global Hyperthermia Therapy for Cancer Sales Volume by Company (units) & (2021-2026) Table 8. Global Hyperthermia Therapy for Cancer Sales Volume Share by Company (2021-2026) Table 9. Global Hyperthermia Therapy for Cancer Average Price (USD/unit) of Company (2021-2026) Table 10. Global Hyperthermia Therapy for Cancer Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hyperthermia Therapy for Cancer Key Company Manufacturing Base & Headquarters Table 12. Global Hyperthermia Therapy for Cancer Company, Product Type & Application Table 13. Global Hyperthermia Therapy for Cancer Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hyperthermia Therapy for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Superficial Hyperthermia Table 18. Significant Companies of Deep Regional Hyperthermia Table 19. Global Hyperthermia Therapy for Cancer Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Hyperthermia Therapy for Cancer Sales Volume by Type (2021-2026) & (units) Table 21. Global Hyperthermia Therapy for Cancer Sales Volume by Type (2027-2032) & (units) Table 22. Global Hyperthermia Therapy for Cancer Sales Volume Share by Type (2021-2026) Table 23. Global Hyperthermia Therapy for Cancer Sales Volume Share by Type (2027-2032) Table 24. Global Hyperthermia Therapy for Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hyperthermia Therapy for Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hyperthermia Therapy for Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hyperthermia Therapy for Cancer Sales Value Share by Type (2021-2026) Table 28. Global Hyperthermia Therapy for Cancer Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Breast Cancer Table 30. Significant Companies of Cervical Cancer Table 31. Significant Companies of Soft Tissue Sarcoma Table 32. Significant Companies of Melanoma Table 33. Significant Companies of Others Table 34. Global Hyperthermia Therapy for Cancer Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 35. Global Hyperthermia Therapy for Cancer Sales Volume by Application (2021-2026) & (units) Table 36. Global Hyperthermia Therapy for Cancer Sales Volume by Application (2027-2032) & (units) Table 37. Global Hyperthermia Therapy for Cancer Sales Volume Share by Application (2021-2026) Table 38. Global Hyperthermia Therapy for Cancer Sales Volume Share by Application (2027-2032) Table 39. Global Hyperthermia Therapy for Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Hyperthermia Therapy for Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Hyperthermia Therapy for Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Hyperthermia Therapy for Cancer Sales Value Share by Application (2021-2026) Table 43. Global Hyperthermia Therapy for Cancer Sales Value Share by Application (2027-2032) Table 44. Global Hyperthermia Therapy for Cancer Sales by Region: 2021 VS 2025 VS 2032 (units) Table 45. Global Hyperthermia Therapy for Cancer Sales by Region (2021-2026) & (units) Table 46. Global Hyperthermia Therapy for Cancer Sales Market Share by Region (2021-2026) Table 47. Global Hyperthermia Therapy for Cancer Sales by Region (2027-2032) & (units) Table 48. Global Hyperthermia Therapy for Cancer Sales Market Share by Region (2027-2032) Table 49. Global Hyperthermia Therapy for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Hyperthermia Therapy for Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Hyperthermia Therapy for Cancer Sales Value Share by Region (2021-2026) Table 52. Global Hyperthermia Therapy for Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Hyperthermia Therapy for Cancer Sales Value Share by Region (2027-2032) Table 54. Global Hyperthermia Therapy for Cancer Market Average Price (USD/unit) by Region (2021-2026) Table 55. Global Hyperthermia Therapy for Cancer Market Average Price (USD/unit) by Region (2027-2032) Table 56. Global Hyperthermia Therapy for Cancer Sales by Country: 2021 VS 2025 VS 2032 (units) Table 57. Global Hyperthermia Therapy for Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Hyperthermia Therapy for Cancer Sales by Country (2021-2026) & (units) Table 59. Global Hyperthermia Therapy for Cancer Sales Market Share by Country (2021-2026) Table 60. Global Hyperthermia Therapy for Cancer Sales by Country (2027-2032) & (units) Table 61. Global Hyperthermia Therapy for Cancer Sales Market Share by Country (2027-2032) Table 62. Global Hyperthermia Therapy for Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Hyperthermia Therapy for Cancer Sales Value Market Share by Country (2021-2026) Table 64. Global Hyperthermia Therapy for Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Hyperthermia Therapy for Cancer Sales Value Market Share by Country (2027-2032) Table 66. Pyrexar Medical Company Information Table 67. Pyrexar Medical Business Overview Table 68. Pyrexar Medical Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 69. Pyrexar Medical Hyperthermia Therapy for Cancer Product Portfolio Table 70. Pyrexar Medical Recent Development Table 71. Oncotherm Company Information Table 72. Oncotherm Business Overview Table 73. Oncotherm Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Oncotherm Hyperthermia Therapy for Cancer Product Portfolio Table 75. Oncotherm Recent Development Table 76. Andromedic Company Information Table 77. Andromedic Business Overview Table 78. Andromedic Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Andromedic Hyperthermia Therapy for Cancer Product Portfolio Table 80. Andromedic Recent Development Table 81. Yamamoto Vinita Company Information Table 82. Yamamoto Vinita Business Overview Table 83. Yamamoto Vinita Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Yamamoto Vinita Hyperthermia Therapy for Cancer Product Portfolio Table 85. Yamamoto Vinita Recent Development Table 86. Med-Logix Company Information Table 87. Med-Logix Business Overview Table 88. Med-Logix Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Med-Logix Hyperthermia Therapy for Cancer Product Portfolio Table 90. Med-Logix Recent Development Table 91. Thermofield Company Information Table 92. Thermofield Business Overview Table 93. Thermofield Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Thermofield Hyperthermia Therapy for Cancer Product Portfolio Table 95. Thermofield Recent Development Table 96. Celsius42 Company Information Table 97. Celsius42 Business Overview Table 98. Celsius42 Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Celsius42 Hyperthermia Therapy for Cancer Product Portfolio Table 100. Celsius42 Recent Development Table 101. Dongseo Medicare Company Information Table 102. Dongseo Medicare Business Overview Table 103. Dongseo Medicare Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Dongseo Medicare Hyperthermia Therapy for Cancer Product Portfolio Table 105. Dongseo Medicare Recent Development Table 106. ThermaSolutions Company Information Table 107. ThermaSolutions Business Overview Table 108. ThermaSolutions Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. ThermaSolutions Hyperthermia Therapy for Cancer Product Portfolio Table 110. ThermaSolutions Recent Development Table 111. Verthermia Company Information Table 112. Verthermia Business Overview Table 113. Verthermia Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Verthermia Hyperthermia Therapy for Cancer Product Portfolio Table 115. Verthermia Recent Development Table 116. Combat Medical Company Information Table 117. Combat Medical Business Overview Table 118. Combat Medical Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Combat Medical Hyperthermia Therapy for Cancer Product Portfolio Table 120. Combat Medical Recent Development Table 121. Hydrosun Company Information Table 122. Hydrosun Business Overview Table 123. Hydrosun Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Hydrosun Hyperthermia Therapy for Cancer Product Portfolio Table 125. Hydrosun Recent Development Table 126. RanD Biotech Company Information Table 127. RanD Biotech Business Overview Table 128. RanD Biotech Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. RanD Biotech Hyperthermia Therapy for Cancer Product Portfolio Table 130. RanD Biotech Recent Development Table 131. Shenzhen ET Medical Technology Company Information Table 132. Shenzhen ET Medical Technology Business Overview Table 133. Shenzhen ET Medical Technology Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Shenzhen ET Medical Technology Hyperthermia Therapy for Cancer Product Portfolio Table 135. Shenzhen ET Medical Technology Recent Development Table 136. Jiangsu Nova Medical Equipment Company Information Table 137. Jiangsu Nova Medical Equipment Business Overview Table 138. Jiangsu Nova Medical Equipment Hyperthermia Therapy for Cancer Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Jiangsu Nova Medical Equipment Hyperthermia Therapy for Cancer Product Portfolio Table 140. Jiangsu Nova Medical Equipment Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Hyperthermia Therapy for Cancer Distributors List Table 144. Hyperthermia Therapy for Cancer Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Hyperthermia Therapy for Cancer Product Image Figure 2. Global Hyperthermia Therapy for Cancer Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hyperthermia Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hyperthermia Therapy for Cancer Sales (2021-2032) & (units) Figure 5. Global Hyperthermia Therapy for Cancer Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Hyperthermia Therapy for Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Superficial Hyperthermia Image Figure 10. Deep Regional Hyperthermia Image Figure 11. Global Hyperthermia Therapy for Cancer Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Hyperthermia Therapy for Cancer Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hyperthermia Therapy for Cancer Sales Volume Share by Type (2021-2032) Figure 14. Global Hyperthermia Therapy for Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hyperthermia Therapy for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hyperthermia Therapy for Cancer Sales Value Share by Type (2021-2032) Figure 17. Breast Cancer Image Figure 18. Cervical Cancer Image Figure 19. Soft Tissue Sarcoma Image Figure 20. Melanoma Image Figure 21. Others Image Figure 22. Global Hyperthermia Therapy for Cancer Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 23. Global Hyperthermia Therapy for Cancer Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Hyperthermia Therapy for Cancer Sales Volume Share by Application (2021-2032) Figure 25. Global Hyperthermia Therapy for Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Hyperthermia Therapy for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Hyperthermia Therapy for Cancer Sales Value Share by Application (2021-2032) Figure 28. Global Hyperthermia Therapy for Cancer Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 29. Global Hyperthermia Therapy for Cancer Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Hyperthermia Therapy for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Hyperthermia Therapy for Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Hyperthermia Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 33. North America Hyperthermia Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Hyperthermia Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Hyperthermia Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Hyperthermia Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Hyperthermia Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Hyperthermia Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 39. South America Hyperthermia Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Hyperthermia Therapy for Cancer Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Hyperthermia Therapy for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Hyperthermia Therapy for Cancer Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Hyperthermia Therapy for Cancer Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Superficial Hyperthermia
  • Deep Regional Hyperthermia
Applications
  • Breast Cancer
  • Cervical Cancer
  • Soft Tissue Sarcoma
  • Melanoma
  • Others
Companies covered
  • Pyrexar Medical
  • Oncotherm
  • Andromedic
  • Yamamoto Vinita
  • Med-Logix
  • Thermofield
  • Celsius42
  • Dongseo Medicare
  • ThermaSolutions
  • Verthermia
  • Combat Medical
  • Hydrosun
  • RanD Biotech
  • Shenzhen ET Medical Technology
  • Jiangsu Nova Medical Equipment

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hyperthermia Therapy for Cancer Sales Value (2021-2032)
  4. 1.2.2 Global Hyperthermia Therapy for Cancer Sales Volume (2021-2032)
  5. 1.2.3 Global Hyperthermia Therapy for Cancer Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hyperthermia Therapy for Cancer Market Dynamics
  1. 2.1 Hyperthermia Therapy for Cancer Industry Trends
  2. 2.2 Hyperthermia Therapy for Cancer Industry Drivers
  3. 2.3 Hyperthermia Therapy for Cancer Industry Opportunities and Challenges
  4. 2.4 Hyperthermia Therapy for Cancer Industry Restraints
3 Hyperthermia Therapy for Cancer Market by Company
  1. 3.1 Global Hyperthermia Therapy for Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Hyperthermia Therapy for Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Hyperthermia Therapy for Cancer Sales Volume by Company (2021-2026)
  4. 3.4 Global Hyperthermia Therapy for Cancer Average Price by Company (2021-2026)
  5. 3.5 Global Hyperthermia Therapy for Cancer Company Ranking (2024-2026)
  6. 3.6 Global Hyperthermia Therapy for Cancer Company Manufacturing Base and Headquarters
  7. 3.7 Global Hyperthermia Therapy for Cancer Company Product Type and Application
  8. 3.8 Global Hyperthermia Therapy for Cancer Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hyperthermia Therapy for Cancer Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hyperthermia Therapy for Cancer Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hyperthermia Therapy for Cancer Market by Type
  1. 4.1 Hyperthermia Therapy for Cancer Type Introduction
  2. 4.1.1 Superficial Hyperthermia
  3. 4.1.2 Deep Regional Hyperthermia
  4. 4.2 Global Hyperthermia Therapy for Cancer Sales Volume by Type
  5. 4.2.1 Global Hyperthermia Therapy for Cancer Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hyperthermia Therapy for Cancer Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hyperthermia Therapy for Cancer Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hyperthermia Therapy for Cancer Sales Value by Type
  9. 4.3.1 Global Hyperthermia Therapy for Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hyperthermia Therapy for Cancer Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hyperthermia Therapy for Cancer Sales Value Share by Type (2021-2032)
5 Hyperthermia Therapy for Cancer Market by Application
  1. 5.1 Hyperthermia Therapy for Cancer Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Cervical Cancer
  4. 5.1.3 Soft Tissue Sarcoma
  5. 5.1.4 Melanoma
  6. 5.1.5 Others
  7. 5.2 Global Hyperthermia Therapy for Cancer Sales Volume by Application
  8. 5.2.1 Global Hyperthermia Therapy for Cancer Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Hyperthermia Therapy for Cancer Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Hyperthermia Therapy for Cancer Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Hyperthermia Therapy for Cancer Sales Value by Application
  12. 5.3.1 Global Hyperthermia Therapy for Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Hyperthermia Therapy for Cancer Sales Value by Application (2021-2032)
  14. 5.3.3 Global Hyperthermia Therapy for Cancer Sales Value Share by Application (2021-2032)
6 Hyperthermia Therapy for Cancer Regional Sales and Value Analysis
  1. 6.1 Global Hyperthermia Therapy for Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hyperthermia Therapy for Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global Hyperthermia Therapy for Cancer Sales by Region: 2021-2026
  4. 6.2.2 Global Hyperthermia Therapy for Cancer Sales by Region (2027-2032)
  5. 6.3 Global Hyperthermia Therapy for Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hyperthermia Therapy for Cancer Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hyperthermia Therapy for Cancer Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hyperthermia Therapy for Cancer Sales Value by Region (2027-2032)
  9. 6.5 Global Hyperthermia Therapy for Cancer Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hyperthermia Therapy for Cancer Sales Value (2021-2032)
  12. 6.6.2 North America Hyperthermia Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hyperthermia Therapy for Cancer Sales Value (2021-2032)
  15. 6.7.2 Europe Hyperthermia Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hyperthermia Therapy for Cancer Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hyperthermia Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hyperthermia Therapy for Cancer Sales Value (2021-2032)
  21. 6.9.2 South America Hyperthermia Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hyperthermia Therapy for Cancer Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hyperthermia Therapy for Cancer Sales Value Share by Country, 2025 VS 2032
7 Hyperthermia Therapy for Cancer Country-level Sales and Value Analysis
  1. 7.1 Global Hyperthermia Therapy for Cancer Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hyperthermia Therapy for Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hyperthermia Therapy for Cancer Sales by Country (2021-2032)
  4. 7.3.1 Global Hyperthermia Therapy for Cancer Sales by Country (2021-2026)
  5. 7.3.2 Global Hyperthermia Therapy for Cancer Sales by Country (2027-2032)
  6. 7.4 Global Hyperthermia Therapy for Cancer Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hyperthermia Therapy for Cancer Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hyperthermia Therapy for Cancer Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hyperthermia Therapy for Cancer Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hyperthermia Therapy for Cancer Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hyperthermia Therapy for Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pyrexar Medical
  2. 8.1.1 Pyrexar Medical Company Information
  3. 8.1.2 Pyrexar Medical Business Overview
  4. 8.1.3 Pyrexar Medical Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pyrexar Medical Hyperthermia Therapy for Cancer Product Portfolio
  6. 8.1.5 Pyrexar Medical Recent Developments
  7. 8.2 Oncotherm
  8. 8.2.1 Oncotherm Company Information
  9. 8.2.2 Oncotherm Business Overview
  10. 8.2.3 Oncotherm Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Oncotherm Hyperthermia Therapy for Cancer Product Portfolio
  12. 8.2.5 Oncotherm Recent Developments
  13. 8.3 Andromedic
  14. 8.3.1 Andromedic Company Information
  15. 8.3.2 Andromedic Business Overview
  16. 8.3.3 Andromedic Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Andromedic Hyperthermia Therapy for Cancer Product Portfolio
  18. 8.3.5 Andromedic Recent Developments
  19. 8.4 Yamamoto Vinita
  20. 8.4.1 Yamamoto Vinita Company Information
  21. 8.4.2 Yamamoto Vinita Business Overview
  22. 8.4.3 Yamamoto Vinita Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Yamamoto Vinita Hyperthermia Therapy for Cancer Product Portfolio
  24. 8.4.5 Yamamoto Vinita Recent Developments
  25. 8.5 Med-Logix
  26. 8.5.1 Med-Logix Company Information
  27. 8.5.2 Med-Logix Business Overview
  28. 8.5.3 Med-Logix Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Med-Logix Hyperthermia Therapy for Cancer Product Portfolio
  30. 8.5.5 Med-Logix Recent Developments
  31. 8.6 Thermofield
  32. 8.6.1 Thermofield Company Information
  33. 8.6.2 Thermofield Business Overview
  34. 8.6.3 Thermofield Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Thermofield Hyperthermia Therapy for Cancer Product Portfolio
  36. 8.6.5 Thermofield Recent Developments
  37. 8.7 Celsius42
  38. 8.7.1 Celsius42 Company Information
  39. 8.7.2 Celsius42 Business Overview
  40. 8.7.3 Celsius42 Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Celsius42 Hyperthermia Therapy for Cancer Product Portfolio
  42. 8.7.5 Celsius42 Recent Developments
  43. 8.8 Dongseo Medicare
  44. 8.8.1 Dongseo Medicare Company Information
  45. 8.8.2 Dongseo Medicare Business Overview
  46. 8.8.3 Dongseo Medicare Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Dongseo Medicare Hyperthermia Therapy for Cancer Product Portfolio
  48. 8.8.5 Dongseo Medicare Recent Developments
  49. 8.9 ThermaSolutions
  50. 8.9.1 ThermaSolutions Company Information
  51. 8.9.2 ThermaSolutions Business Overview
  52. 8.9.3 ThermaSolutions Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ThermaSolutions Hyperthermia Therapy for Cancer Product Portfolio
  54. 8.9.5 ThermaSolutions Recent Developments
  55. 8.10 Verthermia
  56. 8.10.1 Verthermia Company Information
  57. 8.10.2 Verthermia Business Overview
  58. 8.10.3 Verthermia Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Verthermia Hyperthermia Therapy for Cancer Product Portfolio
  60. 8.10.5 Verthermia Recent Developments
  61. 8.11 Combat Medical
  62. 8.11.1 Combat Medical Company Information
  63. 8.11.2 Combat Medical Business Overview
  64. 8.11.3 Combat Medical Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Combat Medical Hyperthermia Therapy for Cancer Product Portfolio
  66. 8.11.5 Combat Medical Recent Developments
  67. 8.12 Hydrosun
  68. 8.12.1 Hydrosun Company Information
  69. 8.12.2 Hydrosun Business Overview
  70. 8.12.3 Hydrosun Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hydrosun Hyperthermia Therapy for Cancer Product Portfolio
  72. 8.12.5 Hydrosun Recent Developments
  73. 8.13 RanD Biotech
  74. 8.13.1 RanD Biotech Company Information
  75. 8.13.2 RanD Biotech Business Overview
  76. 8.13.3 RanD Biotech Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 RanD Biotech Hyperthermia Therapy for Cancer Product Portfolio
  78. 8.13.5 RanD Biotech Recent Developments
  79. 8.14 Shenzhen ET Medical Technology
  80. 8.14.1 Shenzhen ET Medical Technology Company Information
  81. 8.14.2 Shenzhen ET Medical Technology Business Overview
  82. 8.14.3 Shenzhen ET Medical Technology Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shenzhen ET Medical Technology Hyperthermia Therapy for Cancer Product Portfolio
  84. 8.14.5 Shenzhen ET Medical Technology Recent Developments
  85. 8.15 Jiangsu Nova Medical Equipment
  86. 8.15.1 Jiangsu Nova Medical Equipment Company Information
  87. 8.15.2 Jiangsu Nova Medical Equipment Business Overview
  88. 8.15.3 Jiangsu Nova Medical Equipment Hyperthermia Therapy for Cancer Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Jiangsu Nova Medical Equipment Hyperthermia Therapy for Cancer Product Portfolio
  90. 8.15.5 Jiangsu Nova Medical Equipment Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hyperthermia Therapy for Cancer Value Chain Analysis
  2. 9.1.1 Hyperthermia Therapy for Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hyperthermia Therapy for Cancer Sales Mode & Process
  6. 9.2 Hyperthermia Therapy for Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hyperthermia Therapy for Cancer Distributors
  9. 9.2.3 Hyperthermia Therapy for Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst